Lixte Biotechnology Holdings, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Monopar Therapeutics, Inc.

Benitec Biopharma, Inc.

Lixte Biotechnology Holdings, Inc.

Exicure, Inc.

Brainstorm Cell Therapeutics, Inc.

Avalon GloboCare Corp.

Atreca, Inc.

CohBar, Inc.

ContraFect Corp.

Kintara Therapeutics, Inc.

Applied Molecular Transport, Inc.

Why is Lixte Biotechnology Holdings, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Lixte Biotechnology Holdings, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Lixte Biotechnology Holdings, Inc.

826.87%

1.37

146.82%

S&P 500

22.24%

1.67

13.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-11.26%

EBIT to Interest (avg)

-3.54

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.19

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

13.94%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.04

EV to EBIT

-4.98

EV to EBITDA

-4.98

EV to Capital Employed

-19.42

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-79.40%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

EPS(Q)

Highest at USD -0.18

-21What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -1.99 MM has Fallen at -180.12%

NET PROFIT(Q)

At USD -1.92 MM has Fallen at -171.11%

OPERATING CASH FLOW(Y)

Lowest at USD -4.34 MM

ROCE(HY)

Lowest at -158.69%

OPERATING PROFIT(Q)

Lowest at USD -1.99 MM

DEBT-EQUITY RATIO (HY)

Highest at -27.61 %

Here's what is working for Lixte Biotechnology Holdings, Inc.

EPS

Highest at USD -0.18

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Lixte Biotechnology Holdings, Inc.

Pre-Tax Profit

At USD -1.99 MM has Fallen at -180.12%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -1.92 MM has Fallen at -171.11%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit

Lowest at USD -1.99 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite negative

Operating Profit (USD MM)

Operating Cash Flow

Lowest at USD -4.34 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Highest at -27.61 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio